AbbVie earnings date and guidance
AbbVie next results are expected on October 30, 2026. The key thing to watch in AbbVie results is medicine demand after the Apogee deal charge.
What has AbbVie guided for the year?
AbbVie’s weighted path reaches $283.21 by October 2027 and $313.79 by October 2029, a 23% return including dividends by the final date; it hinges on replacement-franchise growth, earnings conversion and the valuation multiple. Management guides to 2026 adjusted diluted EPS of $13.76–$13.96 and $1,251 million of acquired research and milestone expense, while targeting $31,000 million of combined SKYRIZI and RINVOQ revenue in 2027. The probability-weighted cases are bear, base and bull.
| period guided | low | high | date given | |
|---|---|---|---|---|
| Adjusted Diluted EPS Range | Year to Dec 2026 | 13.76 | 13.96 | Oct 5, 2026 |
| Acquired IPR&D and Milestones Expense | Year to Dec 2026 | 1,251 | 1,251 | Oct 5, 2026 |
| combined Skyrizi and Rinvoq 2027 revenues | Year to Dec 2027 | 31,000 | 31,000 | Jan 31, 2025 |
| Skyrizi revenues | Year to Dec 2027 | 20,000 | 20,000 | Jan 31, 2025 |
| Rinvoq revenues | Year to Dec 2027 | 11,000 | 11,000 | Jan 31, 2025 |
Has AbbVie kept its past promises?
The annual bonus focuses on the business replacing Humira, AbbVie’s older blockbuster medicine. “Platform Revenue” means sales excluding Humira, adjusted for currency. It reached $56.3 billion against a $53.7 billion target in 2025. That measure asks whether management is building the next engine of the company rather than receiving credit for sales that were expected to fade.
The promise showed progress. AbbVie’s 2025 revenue reached $61.160 billion, up 8.6%. Adjusted earnings per share, however, fell 1.2% to $10.00, partly reflecting the cost of acquired research and milestones. “Adjusted” figures can help compare operations, but excluded costs still matter to shareholders.
What has AbbVie reported in recent results?
| Quarter to Jun 2026 | Quarter to Mar 2026 | Quarter to Dec 2025 | Quarter to Sep 2025 | Quarter to Jun 2025 | Quarter to Mar 2025 | Quarter to Dec 2024 | Quarter to Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16,990 | 15,002 | 16,618 | 15,776 | 15,423 | 13,343 | 15,102 | 14,460 |
| Gross margin (calculated) | 74.7% | 71.9% | 72.6% | 66.4% | 71.8% | 70.0% | 70.9% | 70.9% |
| Operating income | 6,432 | 3,990 | 4,544 | 1,904 | 4,894 | 3,733 | -1,490 | 3,831 |
| Net income | 3,613 | 695 | 1,816 | 186 | 938 | 1,286 | -22 | 1,561 |
| EPS, diluted | 2.03 | 0.39 | 1.02 | 0.10 | 0.52 | 0.72 | -0.02 | 0.88 |
What should I watch in AbbVie results?
The first checkpoint is October 30, when the company reports its third-quarter results. This is the first report containing Apogee after its September closing. Investors should examine medicine demand, the effect of disclosed deal charges, and the change in cash and debt—not just the EPS headline.
Apogee’s lead program was expected to begin major eczema trials in the second half of 2026, with maintenance results following in 2027. Other pipeline milestones cover skin disease, lupus, blood cancers and eye disease. A planned readout provides information; it does not guarantee approval.